Literature DB >> 3346834

Transport of amantadine and rimantadine through the blood-brain barrier.

R Spector1.   

Abstract

The unidirectional transport of amantadine and rimantadine across cerebral capillaries, the anatomical locus of the blood-brain barrier, was measured with an in situ rat brain perfusion technique. Both rimantadine and, to a lesser extent, amantadine were transported principally across the blood-brain barrier by a saturable transport system with a one-half saturation concentration of about 1.0 mM (either rimantadine or amantadine). The permeability surface area constants were 8.5 x 10(-2) sec-1 (rimantadine) and 1.1 x 10(-2) sec-1 (amantadine) with concentrations of less than 1.0 microM in the perfusate. The extraction of rimantadine and amantadine from the perfusate at low concentrations (less than 1.0 microM) was 88 and 26%, respectively, of the extraction of diazepam which is 100% extracted. Amantadine and rimantadine transport through the blood-brain barrier was significantly inhibited by weakly basic drugs (e.g., diphenhydramine) but not choline (10 mM), probenecid (1 mM) or leucine (1 mM). Inasmuch as both the pKa and percentage ionized at pH = 7.4 of rimantadine (10.4 and 99.9%, respectively) are much higher than that of amantadine (pKa = 9.0 and 97.5%, respectively), and inasmuch as rimantadine is transported into brain much more readily than amantadine, our results suggest that the carrier-mediated transport of the ionized moiety is the crucial process determining the penetration of amantadine and rimantadine through the blood-brain barrier.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3346834

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Solid-state NMR and MD simulations of the antiviral drug amantadine solubilized in DMPC bilayers.

Authors:  Conggang Li; Myunggi Yi; Jun Hu; Huan-Xiang Zhou; Timothy A Cross
Journal:  Biophys J       Date:  2007-09-21       Impact factor: 4.033

2.  Distribution and dynamics of adamantanes in a lipid bilayer.

Authors:  Chee Foong Chew; Andrew Guy; Philip C Biggin
Journal:  Biophys J       Date:  2008-10-03       Impact factor: 4.033

3.  In vitro and in vivo activities of aminoadamantane and aminoalkylcyclohexane derivatives against Trypanosoma brucei.

Authors:  J M Kelly; G Quack; M M Miles
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

4.  Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block.

Authors:  Shashank M Dravid; Kevin Erreger; Hongjie Yuan; Katherine Nicholson; Phuong Le; Polina Lyuboslavsky; Antoine Almonte; Ernest Murray; Cara Mosely; Jeremy Barber; Adam French; Robert Balster; Thomas F Murray; Stephen F Traynelis
Journal:  J Physiol       Date:  2007-02-15       Impact factor: 5.182

5.  Evidence for a central role for PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents.

Authors:  David J Johnson; David A Fidock; Mathirut Mungthin; Viswanathan Lakshmanan; Amar Bir Singh Sidhu; Patrick G Bray; Stephen A Ward
Journal:  Mol Cell       Date:  2004-09-24       Impact factor: 17.970

6.  Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning.

Authors:  Marcel Kaiser; Pascal Mäser; Leela Pavan Tadoori; Jean-Robert Ioset; Reto Brun
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

7.  In depth analysis on the binding sites of adamantane derivatives in HCV (hepatitis C virus) p7 channel based on the NMR structure.

Authors:  Qi-Shi Du; Shu-Qing Wang; Dong Chen; Jian-Zong Meng; Ri-Bo Huang
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

Review 8.  Avian influenza--a review for doctors in travel medicine.

Authors:  W R J Taylor; E Burhan; H Wertheim; P Z Soepandi; P Horby; A Fox; R Benamore; L de Simone; T T Hien; F Chappuis
Journal:  Travel Med Infect Dis       Date:  2009-12-01       Impact factor: 6.211

9.  Molecular docking investigation of the amantadine binding to the enzymes upregulated or downregulated in Parkinson's disease.

Authors:  Mihaela Ileana Ionescu
Journal:  ADMET DMPK       Date:  2020-06-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.